Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention…

By T. Pearson, G. Mensah, R. Alexander, Jeffrey L. Anderson, R. Cannon, M. Criqui, Y. Fadl, S. Fortmann, Yuling Hong, G. Myers and 5 more. Circulation, 2003

5,867 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/dc68c289a2c1ceea361cf9ce11d0343d8eb729ee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. P. Ridker
2. Peter Libby
3. S. Grundy
4. L. Melvin
5. V. Z. Rocha
6. N. Rifai
7. R. Goldberg
8. John B. Buse

In Molecular Biology

1. P. Ridker
2. Peter Libby
3. V. Z. Rocha
4. S. Grundy
5. Julian P. T. Higgins
6. N. Rifai
7. John B. Buse
8. L. Fass

In Surgery

1. P. Ridker
2. Peter Libby
3. L. Melvin
4. V. Z. Rocha
5. S. Grundy
6. R. Goldberg
7. N. Rifai
8. R. Kahn

Citations in the corpus

• The metabolic syndrome: time for a critical appraisal (2005, positive): “There is also an association between other markers of inflammation and insulin resistance/hyperinsulinaemia [70, 72], as well as inflammation and obesity [77–79], leading some investigators to conclude that inflammation is integrally related to the components of the metabolic syndrome [76, 77, 80].”
• C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. (2007, neutral): “After a comprehensive assay standardization program was completed by the Centers for Disease Control and Prevention, a panel of prevention experts presented in 2003 the first guidelines for use of commercial hsCRP tests as an adjunct to global risk prediction (32).”
• Lipoprotein Management in Patients With Cardiometabolic Risk (2008, background): “However, their additive value as a clinical tool is unclear, especially among patients with CMR (92).”